Private and Public Investments in Biomedical Research

Maya Durvasula, Lisa Ouellette and Heidi Williams ()

AEA Papers and Proceedings, 2021, vol. 111, 341-45

Abstract: Recent policy attention has focused on proposals to reduce prices for drugs that have received public funding. From an implementation perspective, such policies rely on public disclosure of government support for research. In this paper, we highlight two conceptual problems with past attempts to measure these public disclosures and construct a new dataset that corrects for these problems. Our corrected measures suggest that underreporting of public research support is less of an issue than previously thought.

JEL-codes: H51 I11 I18 L65 O32 (search for similar items in EconPapers)
Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.aeaweb.org/doi/10.1257/pandp.20211105 (application/pdf)
https://doi.org/10.3886/E138841V1 (text/html)
https://www.aeaweb.org/doi/10.1257/pandp.20211105.appx (application/pdf)
https://www.aeaweb.org/doi/10.1257/pandp.20211105.ds (application/zip)
Access to full text is restricted to AEA members and institutional subscribers.

Related works:
Working Paper: Private and Public Investments in Biomedical Research (2021)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aea:apandp:v:111:y:2021:p:341-45

Ordering information: This journal article can be ordered from
https://www.aeaweb.org/subscribe.html

DOI: 10.1257/pandp.20211105

Access Statistics for this article

AEA Papers and Proceedings is currently edited by William Johnson and Kelly Markel

More articles in AEA Papers and Proceedings from American Economic Association Contact information at EDIRC.
Bibliographic data for series maintained by Michael P. Albert ().